顺铂和奈达铂的临床应用

doi:10.3760/cma.j.issn.1673-422X.2018.09.011

摘要/Abstract

摘要： 多年的临床研究表明顺铂和奈达铂对大部分实体瘤如头颈部肿瘤、食管癌、肺癌、膀胱癌、卵巢上皮癌、睾丸癌和宫颈癌等有效，并且奈达铂在亚洲地区常常作为顺铂的替代药，但来自Ⅲ期临床试验的证据并不充足，临床医生在使用奈达铂替代顺铂治疗时应谨慎。

关键词: 肿瘤, 顺铂, 奈达铂

Abstract: Cisplatin and nedaplatin have been proved to be effective for most of solid tumors including head and neck cancer, esophageal cancer, lung cancer, bladder cancer, ovary epithelial cancer, testicular cancer and cervical cancer. Nedaplatin is often used as an alternative to cisplatin in Asia. However, the evidence from phase Ⅲ clinical trials is insufficient. Clinicians should be cautious when using nedaplatin to replace cisplatin.

Key words: Neoplasms, Cisplatin, Nedaplatin

乔云锋，李萍，付振明. 顺铂和奈达铂的临床应用[J]. 国际肿瘤学杂志, 2018, 45(8): 561-565.

Qiao Yunfeng, Li Ping, Fu Zhenming. Clinical application of cisplatin and nedaplatin[J]. Journal of International Oncology, 2018, 45(8): 561-565.

参考文献

［1］ Rosenberg B, Van Camp L, Grimley EB, et al. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum (Ⅳ) complexes［J］. J Biol Chem, 1967, 242(6): 13471352. ［2］ Uehara T, Watanabe H, Itoh F, et al. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats［J］. Arch Toxicol, 2005, 79(8): 451460. DOI: 10.1007/s0020400506486. ［3］ Goto T, Takano M, Ohishi R, et al. Single nedaplatin treatment as salvage chemotherapy for platinum/taxaneresistant/refractory epithelial ovarian, tubal and peritoneal cancers［J］. J Obstet Gynaecol Res, 2010, 36(4): 764768. DOI: 10.1111/j.14470756.2010.01217.x. ［4］ Wee JT, Ha TC, Loong SL, et al. Is nasopharyngeal cancer really a "Cantonese cancer"?［J］. Chin J Cancer, 2010, 29(5): 517526. ［5］陈骏, 王文华, 顾健. 奈达铂与顺铂治疗晚期鼻咽癌的有效性和安全性系统分析［J］. 中国药学杂志, 2016, 51(2): 144150. DOI: 10.11669/cpj.2016.02.016. ［6］ Tang C, Wu F, Wang R, et al. Comparison between nedaplatin and cisplatin plus docetaxel combined with intensitymodulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase Ⅱ clinical trial［J］. Am J Cancer Res, 2016, 6(9): 20642075. ［7］ Tang LQ, Chen DP, Guo L, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage ⅡⅣB nasopharyngeal carcinoma: an openlabel, noninferiority, randomised phase 3 trial［J］. Lancet Oncol, 2018, 19(4): 461473. DOI: 10.1016/S14702045(18)301049. ［8］ Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008［J］. Int J Cancer, 2010, 127(12): 28932917. DOI: 10.1002/ijc.25516. ［9］ Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013［J］. CA Cancer J Clin, 2013, 63(1): 1130. DOI: 10.3322/caac.21166. ［10］ Ettinger DS, Akerley W, Borqhaei H, et al. Nonsmall cell lung cancer, version 2.2013［J］. J Natl Compr Canc Netw, 2013, 11(6): 645653; quiz 653. DOI: 10.6004/jnccn.2013.0084. ［11］ Suehisa H, Toyooka S. Adjuvant chemotherapy for completely resected nonsmallcell lung cancer［J］. Acta Medica Okayama, 2009, 63(5): 223230. DOI: 10.18926/AMO/31842. ［12］ Li CH, Liu MY, Liu W, et al. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced nonsmall cell lung cancer［J］. Asian Pac J Cancer Prev, 2014, 15(2): 731736. DOI: 10.7314/APJCP.2014.15.2.731. ［13］ Mitani A, Jo T, Yasunaga H, et al. Venous thromboembolic events in patients with lung cancer treated with cisplatinbased versus carboplatin/nedaplatinbased chemotherapy［J］. Anticancer Drugs, 2018, 29(6): 560564. DOI: 10.1097/CAD.0000000000000625. ［14］ Haddad TC, Greeno EW. Chemotherapyinduced thrombosis［J］. Thromb Res, 2006, 118(5): 555568. DOI: 10.1016/j.thromres.2005.10.015. ［15］ Liu Y, Yu S, Liu S, et al. Comparison of nedaplatinbased versus cisplatinbased chemotherapy for advanced nonsmall cell lung cancer among East Asian populations: a metaanalysis［J］. Sci Rep, 2015, 5: 10516. DOI: 10.1038/srep10516. ［16］ Shukuya T, Yamanaka T, Seto T, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, openlabel, phase 3 trial［J］. Lancet Oncol, 2015, 16(16): 16301638. DOI: 10.1016/S14702045(15)003058. ［17］ Horita N, Nagashima A, Nakashima K, et al. The best platinum regimens for chemonaive incurable nonsmall cell lung cancer: network metaanalysis［J］. Sci Rep, 2017, 7(1): 13185. DOI: 10.1038/s41598017137242. ［18］ Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014［J］. CA Cancer J Clin, 2014, 64(1): 929. DOI: 10.3322/caac.21208. ［19］ Zhao P, Dai M, Chen W, et al. Cancer trends in China［J］. Jpn J Clin Oncol, 2010, 40(4): 281285. DOI: 10.1093/jjco/hyp187. ［20］ Rustgi AK, ElSerag HB. Esophageal carcinoma［J］. N Engl J Med, 2014, 371(26): 24992509. DOI: 10.1056/NEJMra1314530. ［21］ Yamashita H, Nakagawa K, Tago M, et al. Radiation therapy combined with cisdiammineglycolatoplatinum (nedaplatin) and 5fluorouracil for Japanese stage ⅡⅣ esophageal cancer compared with cisplatin plus 5fluorouracil regimen: a retrospective study［J］. Dis Esophagus, 2006, 19(1): 1519. DOI: 10.1111/j.14422050.2006.00531.x. ［22］ Fujita Y, Hiramatsu M, Kawai M, et al. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5fluorouracil: a retrospective study［J］. Dis Esophagus, 2008, 21(6): 496501. DOI: 10.1111/j.14422050.2007.00806.x. ［23］ Zhang F, Wang Y, Wang ZQ, et al. Efficacy and safety of cisplatinbased versus nedaplatinbased regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and metaanalysis［J］. Dis Esophagus, 2016, 30(2): 18. DOI: 10.1111/dote.12490. ［24］ Laack E, Andritzky B, Dürk H, et al. Docetaxel and cisplatin as firstline treatment for patients with metastatic esophageal cancer: a pilot study［J］. Onkologie, 2005, 28(12): 647650. DOI: 10.1159/000089102. ［25］ Zhang X, Shen L, Li J, et al. A phase Ⅱ trial of paclitaxel and cisplatin in patients with advanced squamouscell carcinoma of the esophagus［J］. Am J Clin Oncol, 2008, 31(1): 2933. DOI: 10.1097/COC.0b013e3181131ca9. ［26］ Jin J, Xu X, Wang F, et al. Secondline combination chemotherapy with docetaxel and nedaplatin for Cisplatinpretreated refractory metastatic/recurrent esophageal squamous cell carcinoma［J］. J Thorac Oncol, 2009, 4(8): 10171021. DOI: 10.1097/JTO.0b013e3181add9c7. ［27］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65: 87108. DOI: 10.3322/caac.21262. ［28］ Gaffney DK, EricksonWittmann BA, Jhingran A, et al. ACR appropriateness criteria on advanced cervical cancer expert panel on radiation oncologygynecology［J］. Int J Radiat Oncol Biol Phys, 2011, 81(3): 609614. DOI: 10.1016/j.ijrobp.2010.11.005. ［29］ Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions［J］. J Clin Oncol, 2007, 25(20): 29522965. DOI: 10.1200/JCO.2007.10.8324. ［30］ Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer［J］. N Engl J Med, 1999, 340(15): 11441153. DOI: 10.1056/NEJM199904153401502. ［31］ Zuliani AC, Esteves SC, Teixeira LC, et al. Concomitant cisplatin plus radiotherapy and highdoserate brachytherapy versus radiotherapy alone for stage ⅢB epidermoid cervical cancer: a randomized controlled trial［J］. J Clin Oncol, 2014, 32(6): 542547. DOI: 10.1200/JCO.2013.50.1205. ［32］ Jung HS, Erkin OC, Kwon MJ, et al. The synergistic therapeutic effect of cisplatin with human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo［J］. Int J Cancer, 2012, 130(8): 19251936. DOI: 10.1002/ijc.26197. ［33］王海红. 顺铂与奈达铂同步放化疗治疗中晚期宫颈癌的临床对比研究［J］. 中国医药指南, 2015, 13(5): 131132. DOI: 10.15912/j.cnki.gocm.2015.05.094. ［34］ Kagabu M, Shoji T, Murakami K, et al. Clinical efficacy of nedaplatinbased concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study［J］. Int J Clin Oncol, 2016, 21(4): 735740. DOI: 10.1007/s1014701609464. ［35］ Li P, Zhang R, Nie Z, et al. Comparison of nedaplatin and cisplatinbased concurrent chemoradiotherapy in locally advanced cervical cancer patients: a propensity score analysis［J］. Int J Gynecol Cancer, 2018, 28(5): 10291037. DOI: 10.1097/IGC.0000000000001265.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.